Believe

Achieve

Clinical Pipeline


Indication (Target) Target Organ Compound Preclinical Phase 1 Phase 2 Phase 3
HCV (miR-122) Liver RG-101

Alport syndrome (miR-21)
Orphan Disease
Kidney RG-012

Partner: Sanofi Genzyme

NASH (miR-103/107)
Type 2 Diabetes/ Pre-diabetes
Liver AZD4076
RG-125

Partner: AstraZeneca

Cholestatic Disease (miR27)
(Multiple Undisclosed Targets)
Liver RGLS5040
ADPKD (miR-17) Kidney RGLS4326
Glioblastoma Multiforme (miR-10b) CNS  
NASH
(undisclosed targets)
Liver
AKI/CKD
(undisclosed targets)
Kidney

 

Indication (Target) Target Organ / Compound Phase
HCV (miR-122) Liver / RG-101 Ph2
Alport syndrome (miR-21)
Orphan Disease
Kidney / RG-012 Ph2
Partner: Sanofi Genzyme
NASH (miR-103/107)
Type 2 Diabetes/ Pre-diabetes
Liver / AZD4076
RG-125
Ph2
Partner: AstraZeneca
Cholestatic Disease (miR27)
(Multiple Undisclosed Targets)
Liver / RGLS5040 PreClin
ADPKD (miR-17) Kidney / RGLS4326 PreClin
Glioblastoma Multiforme (miR-10b) CNS PreClin
NASH
(undisclosed targets)
Liver PreClin
AKI/CKD
(undisclosed targets)
Kidney PreClin